Penumbra, Inc designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone510-748-3200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$444.94 million
Profitability
Miscellaneous
Employees2,200
Next Earnings Date8/6/2019 (Estimated)
OptionableOptionable
Penumbra (NYSE:PEN) Frequently Asked Questions
What is Penumbra's stock symbol?
Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN."
How were Penumbra's earnings last quarter?
Penumbra Inc (NYSE:PEN) announced its earnings results on Tuesday, May, 7th. The company reported $0.23 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.13 by $0.10. The business earned $128.44 million during the quarter, compared to analysts' expectations of $123.09 million. Penumbra had a net margin of 2.51% and a return on equity of 5.84%. The firm's revenue was up 25.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.15 earnings per share. View Penumbra's Earnings History.
When is Penumbra's next earnings date?
What price target have analysts set for PEN?
7 equities research analysts have issued 1-year target prices for Penumbra's shares. Their forecasts range from $152.00 to $180.00. On average, they anticipate Penumbra's stock price to reach $167.20 in the next twelve months. This suggests a possible upside of 0.1% from the stock's current price. View Analyst Price Targets for Penumbra.
What is the consensus analysts' recommendation for Penumbra?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Penumbra.
What are Wall Street analysts saying about Penumbra stock?
Here are some recent quotes from research analysts about Penumbra stock:
- 1. According to Zacks Investment Research, "Penumbra, Inc. is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The company's portfolio of products primarily addresses neuro and peripheral vascular medical conditions and clinical needs. Neuro products include Neurovascular Access, Neuron Access System, BENCHMARK Intracranial Access System, Penumbra System, 3D, Penumbra Coil 400, Penumbra SMART Coil and LIBERTY stent. Peripheral vascular products include Ruby Coil System, Penumbra Occlusion Device and Indigo System. It operates primarily in U.S., Europe, Canada and Australia. Penumbra, Inc. is headquartered in Alameda, California. " (5/11/2019)
- 2. Canaccord Genuity analysts commented, "We followed up with management this morning and discerned several noteworthy details about the firm’s newest aspiration system. PEN’s newest aspiration catheter includes three critical improvements and upgrades to PEN’s own ACE 68 catheter, further distancing and differentiating PEN from the competition in clot aspiration within the acute ischemic stroke market, in our view: 1. Larger diameter – JET 7 has the largest internal diameter of any aspiration catheter ever cleared – 0.72 inner diameter compared to PEN’s previous 0.68 catheter (Ace 68) – with JET 7’s larger diameter driving a significant increase in the number of cases in which the entire is able to be aspirated almost immediately (within 1-2 minutes)." (8/20/2018)
Has Penumbra been receiving favorable news coverage?
Media coverage about PEN stock has been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Penumbra earned a daily sentiment score of 1.4 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Penumbra.
Who are some of Penumbra's key competitors?
Some companies that are related to Penumbra include ResMed (RMD), Teleflex (TFX), DexCom (DXCM), ABIOMED (ABMD), Hill-Rom (HRC), Insulet (PODD), Haemonetics (HAE), Novocure (NVCR), ICU Medical (ICUI), Integra Lifesciences (IART), Globus Medical (GMED), Tandem Diabetes Care (TNDM), Cantel Medical (CMD), Merit Medical Systems (MMSI) and NuVasive (NUVA).
What other stocks do shareholders of Penumbra own?
Who are Penumbra's key executives?
Penumbra's management team includes the folowing people:
- Mr. Adam Elsesser, Co Founder, Chairman, CEO & Pres (Age 57)
- Dr. Arani Bose, Co-Founder, Chief Innovator and Director (Age 57)
- Mr. Sridhar N. Kosaraju, CFO and Head of Strategy (Age 41)
- Ms. Lynn Rothman, Chief Bus. Officer and Exec. VP (Age 58)
- Mr. Daniel Donen Davis, Chief Commercial Officer (Age 41)
Who are Penumbra's major shareholders?
Penumbra's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (14.96%), Baillie Gifford & Co. (2.67%), Clearbridge Investments LLC (2.34%), William Blair Investment Management LLC (1.98%), Redmile Group LLC (0.93%) and OppenheimerFunds Inc. (0.91%). Company insiders that own Penumbra stock include Adam Elsesser, Arani Bose, Bridget O'rourke, Daniel Donen Davis, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Lynn Rothman, Robert D Evans, Sridhar Kosaraju and Thomas Wilder. View Institutional Ownership Trends for Penumbra.
Which institutional investors are selling Penumbra stock?
PEN stock was sold by a variety of institutional investors in the last quarter, including Champlain Investment Partners LLC, First Trust Advisors LP, Federated Investors Inc. PA, Los Angeles Capital Management & Equity Research Inc., Kennedy Capital Management Inc., First Republic Investment Management Inc., Victory Capital Management Inc. and Timpani Capital Management LLC. Company insiders that have sold Penumbra company stock in the last year include Adam Elsesser, Arani Bose, Bridget O'rourke, Daniel Donen Davis, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Robert D Evans, Sridhar Kosaraju and Thomas Wilder. View Insider Buying and Selling for Penumbra.
Which institutional investors are buying Penumbra stock?
PEN stock was acquired by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Redmile Group LLC, FMR LLC, Clearbridge Investments LLC, Azimuth Capital Management LLC, OppenheimerFunds Inc., Oak Ridge Investments LLC and Stephens Investment Management Group LLC. View Insider Buying and Selling for Penumbra.
How do I buy shares of Penumbra?
Shares of PEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Penumbra's stock price today?
One share of PEN stock can currently be purchased for approximately $166.95.
How big of a company is Penumbra?
Penumbra has a market capitalization of $5.80 billion and generates $444.94 million in revenue each year. The company earns $6.60 million in net income (profit) each year or $0.51 on an earnings per share basis. Penumbra employs 2,200 workers across the globe.View Additional Information About Penumbra.
What is Penumbra's official website?
How can I contact Penumbra?
Penumbra's mailing address is One Penumbra Place, Alameda CA, 94502. The company can be reached via phone at 510-748-3200 or via email at [email protected]
MarketBeat Community Rating for Penumbra (NYSE PEN)
MarketBeat's community ratings are surveys of what our community members think about Penumbra and other stocks. Vote "Outperform" if you believe PEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
